Core Viewpoint - Dyadic International, Inc. is advancing its proprietary C1 expression platform for the production of non-mRNA antigens, aiming to address global health challenges such as avian influenza and future pandemics through efficient biomanufacturing [1][3]. Company Overview - Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for human and animal vaccines, therapeutics, and non-pharmaceutical applications including food and wellness [4][5]. - The company utilizes microbial production platforms, particularly the C1-cell protein production platform based on the fungus Thermothelomyces heterothallica, to enhance the development and reduce costs of biologic vaccines and drugs [5][6]. Upcoming Presentation - CEO Mark Emalfarb will present at the 2025 World Vaccine Congress in Washington, D.C., discussing the urgent need for smarter biomanufacturing in relation to avian influenza and future pandemics [2][3]. - The presentation will include recent preclinical research data demonstrating the effectiveness of Dyadic's C1 platform in producing non-mRNA antigens that generate high neutralizing antibodies [3]. Strategic Focus - Dyadic is leveraging its microbial platform technologies for various applications, including human and animal vaccines, therapeutics, and food-related products, to meet the growing demand for rapid-response solutions in global health [6].
Dyadic to Present at World Vaccine Congress | Washington